LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 3 of 15: Cell count and relative growth within biological replicate 3. - Dataset - HMS LINCS Database

LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 3 of 15: Cell count and relative growth within biological replicate 3. - Dataset (ID:20239)

Download: Excel (XLSX), Comma-separated (CSV)

<<<<

Select the entities to show:

Small molecules	Cells

|<
<<
Previous
Page 34 of 497
Next
>>
>
826 to 850 of 12420 records
per page:

Cell	Small Molecule	Small Mol Concentration	Small Mol Conc Unit	LJP Library Plate	Replicate	Assay Well	Timepoint	Timepoint Unit	Total Cell Count Before Treatment	Total Cell Count After Treatment	Total Control Cell Count	Relative Cell Count	Relative Growth Rate After Treatment
BT-20	R406	0.37	uM	LJP6	1	C16	72	hr	1097	3719	3769	0.9866	0.9811
BT-20	R406	0.37	uM	LJP6	2	C16	72	hr	1097	3219	3769	0.8540	0.7940
BT-20	R406	0.37	uM	LJP6	3	C16	72	hr	1097	3456	3769	0.9168	0.8827
BT-20	Pictilisib	0.37	uM	LJP6	1	D22	72	hr	1097	2009	3769	0.5330	0.3412
BT-20	Pictilisib	0.37	uM	LJP6	2	D22	72	hr	1097	1847	3769	0.4900	0.2806
BT-20	Pictilisib	0.37	uM	LJP6	3	D22	72	hr	1097	1716	3769	0.4552	0.2315
BT-20	Gefitinib	0.37	uM	LJP6	1	N10	72	hr	1097	3395	3769	0.9006	0.8598
BT-20	Gefitinib	0.37	uM	LJP6	2	N10	72	hr	1097	3249	3769	0.8619	0.8052
BT-20	Gefitinib	0.37	uM	LJP6	3	N10	72	hr	1097	3249	3769	0.8619	0.8052
BT-20	Geldanamycin	0.37	uM	LJP5	1	O04	72	hr	1097	1125	3769	0.2985	0.0104
BT-20	Geldanamycin	0.37	uM	LJP5	2	O04	72	hr	1097	1119	3769	0.2969	0.0081
BT-20	Geldanamycin	0.37	uM	LJP5	3	O04	72	hr	1097	1030	3769	0.2732	-0.0252
BT-20	Geldanamycin	0.37	uM	LJP6	1	O04	72	hr	1097	947	3769	0.2512	-0.0562
BT-20	Geldanamycin	0.37	uM	LJP6	2	O04	72	hr	1097	883	3769	0.2343	-0.0802
BT-20	Geldanamycin	0.37	uM	LJP6	3	O04	72	hr	1097	1028	3769	0.2727	-0.0259
BT-20	GSK1059615	0.37	uM	LJP5	1	E04	72	hr	1097	1464	3769	0.3884	0.1372
BT-20	GSK1059615	0.37	uM	LJP5	2	E04	72	hr	1097	1410	3769	0.3741	0.1170
BT-20	GSK1059615	0.37	uM	LJP5	3	E04	72	hr	1097	1408	3769	0.3735	0.1163
BT-20	GSK1059615	0.37	uM	LJP6	1	C04	72	hr	1097	1860	3769	0.4934	0.2854
BT-20	GSK1059615	0.37	uM	LJP6	2	C04	72	hr	1097	1659	3769	0.4401	0.2102
BT-20	GSK1059615	0.37	uM	LJP6	3	C04	72	hr	1097	1871	3769	0.4964	0.2895
BT-20	GSK1904529A	0.37	uM	LJP6	1	H22	72	hr	1097	3260	3769	0.8648	0.8093
BT-20	GSK1904529A	0.37	uM	LJP6	2	H22	72	hr	1097	3439	3769	0.9123	0.8763
BT-20	GSK1904529A	0.37	uM	LJP6	3	H22	72	hr	1097	3358	3769	0.8908	0.8460
BT-20	Omipalisib	0.37	uM	LJP6	1	N04	72	hr	1097	647	3769	0.1716	-0.1685

|<
<<
Previous
Page 34 of 497
Next
>>
>
826 to 850 of 12420 records
per page:

HMS LINCS Project

LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 3 of 15: Cell count and relative growth within biological replicate 3. - Dataset (ID:20239)